NOTE: uses cookies for browser optimization and analytics. Click here to learn about our privacy policy.

Bond Amount Increased to $62 Million for Potential Recovery by SSJR Client Apotex After Successful Budesonide Trial

SSJR has secured an additional $2 million bond from AstraZeneca, adding to an existing $60 million bond, to allow recovery of damages and costs sustained by SSJR client Apotex as a result of an injunction improvidently issued by the District Court. If the trial court’s recent decision that the AstraZeneca’s patents are not infringed and invalid is affirmed by the appellate court, Apotex will make a claim for damages and costs to recover the full $62 million in bonds posted by AstraZeneca.

TOPIC TAGS for this article: > Pharma + Biotech > Litigation

986 Bedford Street, Stamford, Connecticut 06905-5619      +1 203 324-6155